The biopharmaceutical company ImmunOs Therapeutics AG has appointed Michael A. Curran, PhD, as Chairman of the Company´s Scientific Advisory Board.
Tay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.
German Medigene AG has acquired global rights to the CD40L-CD28 costimulatory switch receptor that modulates the tumour stroma in order to make T-TCR therapies more effective.